Combining Clinical and Molecular Data to Predict the Benefits of Carmustine Wafers in Newly Diagnosed High-Grade Gliomas-Reference-Cited by-同舟云学术

Combining Clinical and Molecular Data to Predict the Benefits of Carmustine Wafers in Newly Diagnosed High-Grade Gliomas

Published:2018-02 Issue:2 Volume:20 Page:
ISSN:1092-8480
Container-title:Current Treatment Options in Neurology
language:en
Short-container-title:Curr Treat Options Neurol

Author:

Ius Tamara,Cesselli Daniela,Isola Miriam,Toniato Giovanni,Pauletto Giada,Sciacca Giovanni,Fabbro Sara,Pegolo Enrico,Rizzato Simona,Beltrami Antonio Paolo,di Loreto Carla,Skrap Miran

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical)

Link

http://link.springer.com/article/10.1007/s11940-018-0489-2/fulltext.html

Reference58 articles.

1. Chowdhary SA, Ryken T, Newton HB. Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis. J Neurooncol. 2015;122(2):367–82. https://doi.org/10.1007/s11060-015-1724-2 .

2. Stupp R, Mason WP, van den Bent MJ, European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. https://doi.org/10.1056/NEJMoa043330 .

3. Stupp R, Brada M, van den Bent MJ, ESMO Guidelines Working Group et al.. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; Suppl 3: 93–101.

4. Stupp R, Hegi ME, Gorlia T, European Organisation for Research and Treatment of Cancer (EORTC).; Canadian Brain Tumor Consortium.; CENTRIC study team, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;10:1100–8.

5. Sanai N, Berger MS. Extent of resection influences outcomes for patients with gliomas. Rev. Neurol. 2011;167(10):648–54. https://doi.org/10.1016/j.neurol.2011.07.004 .

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Local therapy in glioma: An evolving paradigm from history to horizons (Review);Oncology Letters;2024-07-17

2. Machine learning to improve interpretability of clinical, radiological and panel-based genomic data of glioma grade 4 patients undergoing surgical resection;Journal of Translational Medicine;2023-07-07

3. Newly Diagnosed High-Grade Glioma Surgery with Carmustine Wafers Implantation. A Long-Term Nationwide Retrospective Study;World Neurosurgery;2023-05

4. Recurrent high grade glioma surgery with carmustine wafers implantation: a long-term nationwide retrospective study;Journal of Neuro-Oncology;2023-03-29

5. Surgical management of Glioma Grade 4: technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch®): a systematic review;Journal of Neuro-Oncology;2023-03-24